anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A cosmetic kit comprises at least two compositions, which are packaged separately. The kit comprises silicone compounds (X1), silicone compounds (Y1) and optionally catalysts, with the provision that the compounds (X1), (Y1) and the catalyst when present are not simultaneously in one of the compositions. The compounds (X1) and (Y1) are reacting together by a hydrosilylation reaction when the catalyst is present or by condensation reaction, when they are brought into contact with one another. At least one of the first and second compositions comprising at least one glossy oil. A cosmetic kit comprises at least two compositions, which are packaged separately. The kit comprises at least one silicone compound (X1), at least one silicone compound (Y1) and optionally at least one catalyst, with the provision that the compounds (X1), (Y1) and the catalyst when present are not simultaneously in one of the compositions. The compounds (X1) and (Y1) are reacting together by a hydrosilylation reaction when the catalyst is present or by condensation reaction, when they are brought into contact with one another. At least one of the first and second composition comprising at least one glossy oil. The compounds (X1) and (Y1) and the glossy oil, and their respective amounts, are such that the average gloss of a deposit comprising the two compositions, measured at 60[deg] , is &gt;= 60 out of 100. An independent claim is included for cosmetic method involving the application to the keratin materials, via at least one composition, of the compounds (X1) and (Y1) of which at least one is a silicone compound, and of the optional catalyst, the compounds X1 and Y1 reacting together by hydrosilylation when the catalyst is present or by condensation, when contacted with one another, and of at least one glossy oil, the compounds X1 and Y1 and the ester oil, and their respective amounts, are such that the average gloss of a deposit comprising X1, Y1 and the glossy oil, measured at 60[deg] , is &gt;= 60 out of 100.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation.  &lt;P&gt;SOLUTION: Isolated antibodies which are combined with the epitope on an MAdCAM are disclosed. These compositions are useful in treating diseases or disorders involving α4β7/MAdCAM blockade, as well as inhibiting a primary event in the inflammatory response such as blocking interactions between intercellular adhesion molecules and their ligands. Treatable disorders include infections, especially viral infections, iatrogenic disorders, cholestatic disorders, hereditary disorders, sarcoidosis, organ transplant, and the like. The diagnostic methods of the antibodies can be employed to detect the presence of a disorder or to monitor the course of therapy used to treat the disorder.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To obtain a cleaning agent compsn. with good foaming properties, reduced sliminess after rinsing and reduced irritativeness to skins by compounding a cationic surfactant with a specified polyethyleneimine polymer. CONSTITUTION:A copolymer (A) with repeating units of formulas I and II (wherein R&lt;1&gt; is H, CH3 or C2H5; R&lt;2&gt; is a 4-15C alkyl, aryl or aralkyl) in a wt. ratio of formula I to formula II of 9/1 to 1/9 (polyethyleneimine polymer) and a cationic surfactant (B) (e.g. octadecyltrimethylammonium chloride) are compounded. Even though the cationic surfactant has not only cleaning power but also bactericidal and bacteriostatic actions and is used for a skin cleaning agent for sterilization such as a cationic soap, there exist defects such as poor foaming, coarse foam and remaining of unpleasant sliminess after rinsing. It is possible by the abovedescribed combination to obtain a cleaning agent compsn. with good foaming reduction in unpleasant sliminess after rinsing and reduced irritativeness to the skins.
PURPOSE:To obtain permission fruit juice free from astringent taste and agreeable to take, easily in high yield, by mixing permission fruit with sugar or salt, and collecting the exuded juice. CONSTITUTION:A persimmon fruit is washed with water and dried and the calyx and skin are removed therefrom, or a persimmon fruit is crushed after the removal of the calyx. The persimmon fruit processed above is added with preferably 10wt% sugar (e.g. sucrose) or preferably 5wt% salt (e.g. calcium chloride), and stored for 10 days e.g. at &lt;=15 deg.C to obtain the objective fruit juice.
The present invention, Nalbuphine polyester derivative is related to a novel long acting agent. The chemical structure of Nalbuphine polyester derivative is shown in Formula IV, in which the R is selected from a nonsaturated aliphatic fatty acid, or saturated aliphatic fatty acid; n represents the number of ester groups in Nalbuphine polyester derivative, is an integer in the range of 1 to 4. When R is described by R&#39;CO, the R&#39; denotes the aliphatic group consisting of alkyl or alkylene having 1 to 40 carbon atoms. The aliphatic group is selected from (a) a straight alkyl group, (b) a branched alkyl group, (c) a straight alkyl group where substituted with a benzene ring, (d) a branched alkyl group substituted with a benzene ring, (e) a benzenyl group where benzene ring contains a straight chain aliphatic group, (f) a benzenyl group where benzene ring contains a branch chain of aliphatic group. The present invention also provides the process of preparation method and the long acting preparations of pharmaceutical composition comprising the Nalbuphine polyester derivative. The Nalbuphine polyester derivatives are synthesized by the step; as chlorinated the Nalbuphine base, then carry out the esterification by reacting with nonsaturated fatty acid anhydrides, saturated fatty acid anhydrides, alkyl (C1-40) acids chlorides or alkylene (C1-40) acids chlorides to undergo. The analgesic effect produced by single dose of Nalbuphine polyester derivative was last for 4 to 5 days, such effect was adequate enough for the treatment of acute and chronic pain. The Nalbuphine polyester derivative can be formulated into various dosage forms, the present invention also provides the preparation method to produce a clear injection solution, which was in contrast to traditional suspensions. Besides it had better stability. The advantage of Nalbuphine polyester derivative was to reduce the amount of injection and its long acting analgesic effect.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an ulcerative colitis-inhibiting composition including high amylose starch (HAS) as an effective ingredient because HAS inhibits incidence of ulcerative colitis and has therapeutic effects.  &lt;P&gt;SOLUTION: This chronic ulcerative colitis-inhibiting composition comprises the high amylose starch (HAS) as an effective ingredient. The high amylose starch content is preferably 10-50 wt.% based on the composition and the composition is used preferably in the form of a stick or wafer food. The composition is continuously taken at a dose of 10-70 g/day for an adult. The high amylose starch has better palatability and taste than dietary fibers and can be much ingested continuously and can prevent and treat ulcerative colitis.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an improved method that has a high whitening effect and whitens teeth.  &lt;P&gt;SOLUTION: The composition for whitening teeth comprises a bleaching agent to be suitably applied to the surfaces of teeth to be whitened. The bleaching agent is allowed to stand and act on teeth for 3-30 minutes, is removed from the surfaces of teeth. In the composition, the bleaching agent is suitable for application and removal at least once. The pharmacologically acceptable oxidizing agent for preparing a medicine for whitening teeth accordingly to a treatment plan is used. The kit for whitening teeth is provided.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention relates to a cutaneous muscle regeneration dressing gauze and a preparation method thereof. The method comprises the following steps of: preparing a prescription having the effects of eliminating putridity and engendering flesh; adding the prescription into vegetable oil; soaking the mixture for 2 to 8 days, and then decocting the mixture at a high temperature until the medicament color is yellow brown; and filtering out dregs, and putting the mixture into a sanitary sterile gauze. The prescription is prepared from the following components: gypsum, dragon&#39;s blood, calomel, frankincense, borneal, dragon&#39;s bones, dahurian angelica root and chicken&#39;s gizzard-membrane. The dressing gauze has the effects of cooling blood and resolving toxin, quickening blood and transforming stasis, dispersing swelling and relieving pain, eliminating putridity and engendering new and the like, wherein the vegetable oil contains a great amount of nutrient media to strengthen the nutrition functions to damaged cutaneous muscle. The dressing gauze has the advantages of: good breathable effect, and convenience for growth of new tissues; function of replacing damaged capillaries; and function of regenerating bed nets for growth of the new tissues. The dressing gauze can treat various kinds of burns, scalds, traumas, abscesses, bedsores, bouton and angitis, various skin infections and the like.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide powder having improved dispersibility, a paste comprising the powder and a cosmetic comprising the paste.  &lt;P&gt;SOLUTION: The powder is used for the paste for preparing the cosmetic and the surface thereof is subjected to a coating treatment with aluminum oxide hydrate and/or silicic acid. The oil gel cosmetic comprises the paste prepared by using the coated powder. Titanium dioxide or zinc oxide is preferred as substrate powder of the coated powder. The generation of radicals after absorbing ultraviolet rays is suppressed as accompanying effects.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
One aspect of the invention relates to a method for modifying the gut microbiome, comprising a first step of receiving phenotypic data, medical data, lifestyle data and metagenomic data for a first set of individuals and for a target individual. From these data, a vector is constructed for each individual. This vector is then used to determine a second set of individuals with maximum similarity to the target individual. Among this second set of individuals, a third set of individuals is determined using criteria of gut microbiome richness and/or of absence of metabolic syndrome and/or of glycaemia and/or of waist circumference and/or of cholesterolaemia. A digital profile is generated for each individual of the third set of individuals and for the target individual. The digital profile comprises a value resulting from an evaluation of a score representing the positive or negative influence of a person&#39;s lifestyle on their gut microbiome. Then, data are generated from the lifestyle data of the target individual and digital profiles are generated from these generated lifestyle data. Finally, the digital profiles with maximum similarity with at least one digital profile among the digital profiles generated for each individual of the third set of individuals and having a score greater than the score of the digital profile of the target individual are used to generate at least one recommendation regarding the lifestyle of the target individual.
FIELD: medicine, veterinary science. ^ SUBSTANCE: group of inventions concerns veterinary medicine. An immunogenic dose of the immunogenic material Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus are used for producing a vaccine for combined introduction of the Mycoplasma hyopneumoniae vaccine and the PRRSV vaccine to Mycoplasma hyopneumoniae primed pigs. The immunogenic material Mycoplasma hyopneumoniae and live attenuated PRRS virus either can be, or are either in a common container, or in separate containers, and either mixed before introduction, or introduced consistently within no more than 24 hours. The method of pigs&#39; vaccination implies the stages of primary vaccination (priming) with the Mycoplasma hyopneumoniae vaccine followed with combined vaccination with the immunogenic material Mycoplasma hyopneumoniae and live attenuated PRRS virus with the components Mycoplasma hyopneumoniae and PRRS being introduced consistently within no more than 24 hours. ^ EFFECT: group of inventions allows higher efficacy of mycoplasmosis and PRRSV vaccination in pigs. ^ 6 cl, 2 ex
A method for providing an optimized process in clinical research, comprising enabling research participant, site manager to input research participants&#39; information by enrolment and retention module on research participant computing device, research site manager computing device. Identifying research participants&#39; information stored in database and generating list of qualified research participants by list generating module. Enabling qualified research participants to schedule appointment with site manager by appointment scheduling module and assigning principal investigators to screen research participants. Enabling principal investigators to input screening data by primary source data capture module after screening research participants in real-time. Collecting screening data to calculate accounts receivable from sponsor by financial module and sending screening data to data review and reports generating module. Generating screening reports by data review and reports generating module and sending screening reports to invoice generating module thereby generating invoice. Sending invoice to sponsor computing device and enabling sponsor to review invoice.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a release sheet hard to cause a heavy-releasing phenomenon even if irradiated with radiation, and a pressure-sensitive adhesive element using it.  &lt;P&gt;SOLUTION: The release sheet has a base material and the release agent layer provided on the base material. The release agent layer is mainly constituted of a slicone resin and this silicone resin is characterized in that the occupying ratio of a phenyl group in all of the substituents bonded to the silicon atom constituting the silicone resin is 10-50 mol% and used in radiation sterilization. The silicone resin is a polyorganosiloxane and the weight average molecular weight thereof is 5×10&lt;SP&gt;3&lt;/SP&gt;-1.5×10&lt;SP&gt;6&lt;/SP&gt;. The thickness of the release agent layer is 0.01-3.0 μm.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject agent having high safety and stability and excellent melanin suppressing effect by using an extract of a fruit of a specific shrub having high contents of vitamin C, minerals, etc., and used as a food and drink. SOLUTION: An extract of camocamo (Myrciaria dubia) is used as an active component of the agent. Camocamo is fruit of an edible shrub plant belonging to the family Myrtaceae and growing on the river bank or the water-flowing bank of lakes of the Amazon basin extending from the eastern part of Peru to the western north part of Brazil. Raw, semi-dried or dried fruit can be used as the extraction raw material and the raw material is preferably used in pulverized state. The camocamo extract is easily produced by extracting the raw material with water, a hydrophilic organic solvent or their mixture. The melanin suppressing agent is topically applied to the diseased part such as the spot, freckle, pigmented part caused by sunburn, etc. The amount of the agent to be applied to 1cm&lt;2&gt; of the skin is about 0.5-10mg for a creamy or ointment preparation and about 1-15mg for a liquid preparation.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new method for producing a phosphorus-substituted porphyrin compound, by which various kinds of phosphorous functional groups can freely be introduced into the porphyrin ring.  &lt;P&gt;SOLUTION: This method for producing the phosphine-substituted porphyrin compound is characterized by coupling-reacting a halogen-substituted porphyrin compound with a secondary phosphine in the presence of a transition metal as a catalyst. The phosphine-substituted porphyrin compound can be subjected to a reaction such as an oxidation reaction to convert into the phosphine oxide-substituted porphyrin compound. The halogen-substituted porphyrin compound can be coupled with a phosphite in the presence of a transition metal as a catalyst to produce the phosphonate-substituted porphyrin compound. The phosphonate-substituted porphyrin compound can be subjected to a reaction such as an ester-eliminating reaction to convert into the phosphonate-substituted porphyrin compound.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain an enzyme-containing internal liquid medicine having high storage stability, being readily taken in use, rapidly showing effect. SOLUTION: This enzyme-containing internal liquid medicine is obtained by mixing a fat digesting enzyme solution (e.g. lipase AP6) with 10-30-W/V% of a highly concentrated saccharide (e.g. glucose) and 0.1-1-W/V% of a calcium agent (e.g. calcium chloride). The minimum amount of the fat digesting enzyme agent mixed is preferably &gt;=50 units per day. The enzyme-containing internal liquid medicine is further mixed with 0.2-10W/V% of a water-soluble component of a crude medicine of one or more of an essence, liquid essence and tincture of cinnamon bark, clove, gentian, ginseng, etc.  The enzyme-containing internal liquid medicine is useful as an internal medicine for stomach and bowels, having effective action of the fat digesting enzyme on indigestion, a dull feeling in the stomach caused by indigestion, an undesirable condition in the stomach etc., further showing healthy stomach effect by adding the crude medicine.
PURPOSE:To immobilize a physiologically active substance in high immobilization efficiency simply and firmly, by polymerizing a glassy supercooled polymerizable monomer at low temperature by light ray or ionizing radiation irradiation to give a porous polymer, bringing the polymer into contact with a physiologically active substance to adoserb the substance on the polymer, and drying the polymer. CONSTITUTION:A glassy supercooled polymerizable monomer[e.g., hydroxyethyl methacrylate, etc.] is blended with water, irradiated with light rays or ionizing radiation at low temperature &lt;=0 deg.C and polymerized, to give a porous polymer. Then, it is added to an aqueous solution of a physiologically active substance (e.g., glucoamylase, etc.), it is in contact with the solution for a given time, so that the physiologically active substance is absorved in or adsorbed on the polymer, and the polymer is dried, so that the physiologically active substance is immobilized to the polymer. The concentration of the monomer in water is preferably 5-90wt%.
A predictive modeling method implemented on a computer for predicting patient outcomes and conditions from medical database records of a population of patients, and an optimization process of iterative variation of parameters of the method to achieve a best precision fit. Individual patient documents are created by concatenation of unstructured text fields from the patient&#39;s medical record, and these are processed using Natural Language Processing. A patient document corpus is built, and terms in the corpus are weighted and mapped to standard vocabularies. A term-by-document matrix is built and its dimensionality is reduced by Latent Semantic Indexing. Patient and term queries are combined and scored, producing a ranked list. The parameters of the model are iteratively optimized for an input list of patients with corresponding health score values.
A computer implemented method for generating a ballpark clinical trial budget based on User (Sponsors/Researchers) input of clinical trial project related specifications and a set of predefined assumptions from a predefined database. The generated budget is graphically displayed in the form of an interactive and completely editable multilevel doughnut chart. The User can then review and edit any of the predefined assumption used in the computation of the budget and save it as a new version of the trial project&#39;s budget. A summary of the budget can also be printed out. The User can review and shortlist the service providers to provide deliverables for the clinical trial and finance management interface enables interaction between the User and the service providers to further discuss. The method can be modified to generate budgets and business intelligence in any organization to aid various operations.
Antibody-mediated rejection (ABMR) is one of the main obstacles to successful transplantation, including ABO blood group-incompatible (ABOi) transplantation. C4d deposition is a marker of ABMR and is also found in most ABOi allograft tissues. Described herein are anti-C4d CAR Tregs that suppress ABMR in ABOi allografts. Anti-C4d CAR Tregs prepared by retroviral transduction of CAR into CD62L +CD4 +CD25 +Tregs, expressed Foxp3, CD25, CTLA-4, LAP, and GITR to similar extents as non-transduced Tregs. Anti-C4d CAR Tregs were activated by specific binding to C4d and suppressed in vitro T cell proliferation as well as non-transduced Tregs. Furthermore, adoptive transfer of anti-C4d CAR Tregs significantly prolonged mouse ABOi heart allograft survival (P&lt;0.05).
PURPOSE:To obtain a composition for external use in the scalp capable of manifesting ultrahigh suppressing effects on dandruff and pruritus and further excellent in persistence of the effects by using an antimicrobial agent used for the purpose of preventing the dandruff and pruritus with a keratinization improving agent. CONSTITUTION:This composition for external use in the scalp is obtained by using an antimicrobial agent which is a preventing agent for dandruff and pruritus and a keratinization improving agent comprising an amine derivative of formula I [R&lt;1&gt; is a 4-40C straight-chain, branched chain or cyclic saturated or unsaturated hydrocarbon; R&lt;2&gt; to R&lt;6&gt; are each H or a 1-10C hydrocarbon (which can be substituted with OH)] or its acid addition salt in combination. An antimicrobial agent selected from a polyvalent metallic salt of 2- mercaptopyridine N-oxide, a 1-hydroxy-2-pyrrolidone derivative of formula II (R&lt;7&gt; is an alkyl, an alkenyl, a cycloalkyl, etc.; R&lt;8&gt; is H, an alkyl, an alkenyl, etc.; X&lt;-&gt; is an organic salt group, a cation, etc.), 2,2&#39;-dithio-bis-(pyridine N-oxide) of formula III and a benzalkonium salt of formula IV (R&lt;13&gt; is a hydrocarbon; Y&lt;-&gt; is an anion residue such as a phosphoric ester) is especially preferred as the antimicrobial agent.
A computer-implemented method, apparatus, and system for servicing the needs of customers with a particular disease or disorder. A catalog of specialty items relevant to the needs of individual customers at a given stage of the disease or disorder or treatment cycle may be provided. Secure personal registries of items selected from the catalog by a customer may be provided. Experts and other third parties may recommend items for inclusion in the personal registry of the customer. Experts, customers, and/or third-parties may recommend additional items for inclusion into the catalog of specialty items. The catalog may also be updated based on sales information. Third parties may make a financial contribution or an in-kind contribution to the customer&#39;s registry. The relationship between the catalog of specialty items, recommenders, and customers, may be managed by the system while the privacy of personal customer data may be maintained.